// App-Quantinova.ai

OT3-01-02 : CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial

Researchers

Presenter

  • M Quintela-Fandino

Principal Investigators

  • L Manso

  • S Mouron

  • JF Lopez-Acosta

  • JA García-Saenz

  • E Holgado

  • T Pascual-Martinez

  • L Medicna

  • J Guerra

  • L Gonzalez-Cortijo

  • S Mañes

Medical Centers

  • Hospital Ramon y Cajal, Madrid, Spain

  • Hospital Quiron, Madrid, Spain

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • Centro Nacional de Biotecnologia/CSIC, Madrid, Spain

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • Hospital Doce de Octubre, Madrid, Spain

  • HLP - Hospital La Princesa, Madrid, Spain

  • Hospital Universitario Fuenlabrada, Fuenlabrada-Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Prostaglandin E2

  • Human epidermal growth factor receptor 2

  • Regulatory T cells

  • T-cell function

Drug/Treatment

  • Bevacizumab

  • Durvalumab

  • tryptophan

  • Dinoprostone

Outcome

  • N/A

Study Design

  • open label

  • adaptive

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved